Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer

  • Authors:
    • Shingo Ashida
    • Ichiro Yamasaki
    • Kenji Tamura
    • Tsutomu Shimamoto
    • Keiji Inoue
    • Shinji Kariya
    • Kana Kobayashi
    • Takuji Yamagami
    • Taro Shuin
  • View Affiliations

  • Published online on: February 22, 2016     https://doi.org/10.3892/mco.2016.786
  • Pages: 789-793
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the feasibility and preliminary outcomes of high-dose-rate (HDR)-brachytherapy as a monotherapy in two fractions within 1 day for localized prostate cancer, including high-/very high-risk cases. Among the 68 patients treated with HDR monotherapy between July 2011 and December 2014, 65 had a minimal follow-up of 12 months without adjuvant androgen deprivation therapy and were enrolled in the present study [42/65 (64.6%) exhibited high-/very high-risk diseases]. HDR monotherapy was performed in two fractions with a minimal interval of 6 h and the prescribed dose was 13.5 Gy (x2). Adverse events (AEs) were assessed using Common Terminology Criteria for Adverse Events (version 4; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40), and biochemical failure was assessed by the Phoenix definition. The median follow‑up time was 30.1 months. The majority of patients had Grade 0‑1 acute AEs. Four patients (6.2%) exhibited urinary retention, requiring a Foley catheter. Grade 3 acute AEs occurred at a frequency of 3.1% and hematuria at 1.5%. The majority of patients also exhibited Grade 0‑1 chronic AEs. Grade 3 chronic AEs occurred at a frequency of 1.5% and urethral stricture at 1.5%, for which endoscopic treatment was indicated. Acute and chronic gastrointestinal AEs were uncommon, and no Grade 3 or above AEs developed. Biochemical failure occurred in 4 patients who all exhibited high‑/very high‑risk diseases. Kaplan‑Meier estimated that 3 year biochemical failure‑free survival was 91.6% overall and 88.0% in high‑/very high-risk cases. The present two‑fraction 1 day HDR monotherapy is feasible with minimal AEs and achieved acceptable biochemical control of localized prostate cancer, including high-/very high-risk cases, although long-term follow-up is required.
View Figures
View References

Related Articles

Journal Cover

May 2016
Volume 4 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ashida, S., Yamasaki, I., Tamura, K., Shimamoto, T., Inoue, K., Kariya, S. ... Shuin, T. (2016). Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer. Molecular and Clinical Oncology, 4, 789-793. https://doi.org/10.3892/mco.2016.786
MLA
Ashida, S., Yamasaki, I., Tamura, K., Shimamoto, T., Inoue, K., Kariya, S., Kobayashi, K., Yamagami, T., Shuin, T."Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer". Molecular and Clinical Oncology 4.5 (2016): 789-793.
Chicago
Ashida, S., Yamasaki, I., Tamura, K., Shimamoto, T., Inoue, K., Kariya, S., Kobayashi, K., Yamagami, T., Shuin, T."Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer". Molecular and Clinical Oncology 4, no. 5 (2016): 789-793. https://doi.org/10.3892/mco.2016.786